Pre-mRNA splicing is a complex regulatory nexus modulated by various trans-factors and their posttranslational modifications to create a dynamic transcriptome through alternative splicing. Signalinduced phosphorylation and dephosphorylation of trans-factors are known to regulate alternative splicing. However, the role of other posttranslational modifications, such as deacetylation/acetylation, methylation, and ubiquitination, that could modulate alternative splicing in either a signal-dependent or -independent manner remain enigmatic. Here, we demonstrate that Scaffold/matrix-associated region-binding protein 1 (SMAR1) negatively regulates alternative splicing through histone deacetylase 6 (HDAC6)-mediated deacetylation of RNA-binding protein Sam68 (Src-associated substrate during mitosis of 68 kDa). SMAR1 is enriched in nuclear splicing speckles and associates with the snRNAs that are involved in splice site recognition. ERK-MAPK pathway that regulates alternative splicing facilitates ERK-1/2-mediated phosphorylation of SMAR1 at threonines 345 and 360 and localizes SMAR1 to the cytoplasm, preventing its interaction with Sam68. We showed that endogenously, SMAR1 through HDAC6 maintains Sam68 in a deacetylated state. However, knockdown or ERK-mediated phosphorylation of SMAR1 releases the inhibitory SMAR1-HDAC6-Sam68 complex, facilitating Sam68 acetylation and alternative splicing. Furthermore, loss of heterozygosity at the Chr.16q24.3 locus in breast cancer cells, wherein the human homolog of SMAR1 (BANP) has been mapped, enhances Sam68 acetylation and CD44 variant exon inclusion. In addition, tail-vein injections in mice with human breast cancer MCF-7 cells depleted for SMAR1 showed increased CD44 variant exon inclusion and concomitant metastatic propensity, confirming the functional role of SMAR1 in regulation of alternative splicing. Thus, our results reveal the complex molecular mechanism underlying SMAR1-mediated signal-dependent and -independent regulation of alternative splicing via Sam68 deacetylation.
Scaffold/matrix-associated region-binding protein 1 (SMAR1) is one such NM-associated protein identified in mouse double-positive thymocytes (6) . The human homolog of SMAR1, BANP, is mapped to chromosome 16q24.3 locus. Loss of heterozygosity (LOH) in this locus is implicated in multiple cancers (7, 8) . SMAR1 delays tumor progression (9, 10) and inhibits the expression of multiple genes (11, 12) . Clinical specimens of different histological grade breast cancer tissues indicated that SMAR1 expression is drastically down-regulated in the higher grades of infiltrating ductal carcinomas (13) .
Cancer cells often take advantage of AS because the spliceosome machinery goes berserk in cancers, resulting in the expression of protein isoforms that promote growth and metabolism of tumor cells (14) (15) (16) . Signal-transduction pathways-such as Ras, PI3-kinase, AKT, ERK, PRP4, and SRPK1-have been reported to be deregulated in cancerous cells (17) . Posttranslational modifications (PTMs) induced by kinases and phosphatases on regulatory factors modulate tumor progression and metastasis, as exemplified by CD44 gene AS (18) (19) (20) (21) . CD44, a cell-surface transmembrane glycoprotein, expresses variant isoforms (CD44v) that increase
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metastatic propensity in multiple tumor types (22) . Generation of CD44v is modulated by AS events, which require activation of the ERK-MAPK pathway (23) . However, a comprehensive role for trans-factors that negatively influences CD44 AS in a signaldependent and -independent manner remains to be established.
Our present study revealed SMAR1 as a negative regulator of CD44 gene AS in a signal-dependent and -independent manner by modulating Sam68 (Src-associated substrate during mitosis of 68 kDa) deacetylation. Here, we document that SMAR1, in cooperation with histone deacetylase 6 (HDAC6), interacts with Sam68 and maintains it in a deacetylated state, concomitantly inhibiting the inclusion of CD44 alternate exons. Furthermore, we show that ERK activation, knockdown of SMAR1, LOH at chromosome 16q24.3 locus, and/or inactivation of HDAC6 enhances Sam68 acetylation and facilitates CD44 variant exon inclusion. Overall, our results demonstrate the role of NMassociated protein SMAR1 in the regulation of AS.
Results

SMAR1 Is Enriched in Splicing
Speckles and Regulates AS. SC35-enriched nuclear speckles are considered as a hallmark of proteins involved in pre-mRNA splicing (24) . Presence of a stretch of serine and proline residues, in addition to interspersed arginine residues in the protein-interaction domain of SMAR1 (SI Appendix, Fig.  S1A ), inspired us to examine the distribution of SMAR1 in the RNP matrix. Initially, we found that the highly abundant SMAR1 protein had a homogenous distribution within the nucleus, making it difficult to resolve its distribution in the RNP matrix and/or its association with SC35-splicing speckles using immunofluorescence (IF) of intact cells. However, in situ immunostaining of NM (25) allowed us to reveal that SMAR1 is enriched in the RNP-rich splicing speckles and colocalizes with SC35 (Fig. 1A , −RNase A). Treatment of NM with RNase A abolished the occurrence of these nuclear speckles (Fig. 1A, +RNase A) , suggesting that SMAR1-enriched speckles are RNPs in nature. Further, RNA immunoprecipitation (RIP) assays showed an association of SMAR1 with spliceosome component snRNAs, U1, U2, U4, U5, and U6 snRNAs that are involved in splice site recognition (Fig. 1B) . Interestingly, affinity of SMAR1 for U5 snRNA is higher than it is for any other snRNA. The specific association of SMAR1 with snRNAs, but not with GAPDH mRNA, prompted us to investigate its effect on the regulation of AS. In vivo splicing assays with minigenes harboring the cis-regulatory elements controlling the AS of either FAS (26) or CD44 (23) revealed that SMAR1 knockdown augments the inclusion of alternative exons, whereas overexpression reduced the exon inclusion ( Fig. 1 C and D and SI Appendix, Fig. S1 B and C). However, to eliminate the possibility that overexpression or knockdown of SMAR1 alters the stability of mRNA splice variants per se, we performed mRNA stability assays using Actinomycin D. Inhibition of transcription by using Actinomycin D in HEK293T cells that were previously cotransfected with either SMAR1 overexpression or knockdown plasmids along with FAS and CD44 minigenes resulted in no change in the observed ratio of spliced mRNAs at any given time point, indicating that SMAR1 expression does not contribute toward the differential stability of mRNA splice variants ( Fig. 1 E and F) . Together, these data indicate that SMAR1 specifically regulates AS without affecting the stability of splice variants.
SMAR1 Knockdown or LOH at Chr.16q24.3 Enhances CD44 Variant Exon Inclusion and Promotes Lung Metastasis. Considering that the levels of SMAR1 are drastically down-regulated in the higher grades of breast tumors (13) , and the inclusion of CD44 variant exons confers invasive and metastatic propensity to tumor cells (27, 28) , we set out to decipher the molecular mechanism underlying SMAR1-mediated regulation of CD44 AS. Semiquantitative exon-specific RT-PCR analysis of CD44 splice variants using different primer sets (20) (Fig. 2A and SI Appendix, Table S1 ) in HeLa cells that are stably expressing a SMAR1-targeting shRNA (Fig. 2B ) revealed an enhanced incorporation of variant exons v2-v6 (proximal variant exons; Fig. 2C ). Interestingly, we observed no significant change in the incorporation of variable exons v7-v10 (distal variant exons; SI Appendix, Fig. S1D , Left) and standard CD44 (CD44s). In corollary, overexpression of SMAR1 (Fig. 1D ) inhibited the inclusion of proximal variant exons (Fig.  1E) , whereas distal variant exons and CD44s remain unaltered F) A measure of mRNA stability of alternatively spliced transcripts upon SMAR1 overexpression and knockdown. Cells were harvested at different time points as indicated after treatment with Actinomycin D and analyzed for stability through measurement of temporal changes in abundance of each splice variant, CD44 (E) and FAS (F). A ratio of relative exon inclusion during overexpression or knockdown of SMAR1 during different time points showed no effect on the stability of mRNA splice variants of target genes. Error bars represent SD from three independent experiments. FV, Flag vector; shCntrl, Control shRNA; shSM, SMAR1 shRNA (sh745). Student's t tests were used to calculate the P values. Differences with P < 0.05 were considered statistically significant.
(SI Appendix, Fig. S1D , Right), indicating that SMAR1 negatively regulates the inclusion of CD44 variable exons v2-v6.
Human breast cancer cells such as MDA-MB-468 and T47D harbor LOH, whereas MCF-7 cells lack LOH (7, 29) . Western blot analysis showed that MDA-MB-468 and T47D cells express minimal amounts of SMAR1, whereas MCF-7 cells express significant amounts of SMAR1, corroborating with the LOH status (Fig. 2F) . Because SMAR1 expression inversely correlates with CD44 variant exon inclusion, we investigated CD44 AS in context of LOH. In MDA-MB-468 and T47D cells, we observed a categorical increase in the inclusion of variant exons v2-v10, whereas CD44 variant exon inclusion is negligible in SMAR1 expressing MCF-7 cells (Fig. 2G and SI Appendix, Fig. S1E, Left) . Nevertheless, ectopic expression of SMAR1 in LOH-harboring MDA-MB-468 and T47D cell lines by using adeno-SMAR1 (Ad-SM) (Fig. 2H ) consistently decreased the inclusion of proximal exons (Fig. 2I) , whereas no significant change was observed in the levels of distal variant exons and CD44s (SI Appendix, Fig. S1E , Right). Together, these data indicate that LOH at 16q24.3 locus, wherein SMAR1 has been mapped, contributes to CD44 AS.
Considering that the inclusion of CD44 variable exons confers the invasive and metastatic proclivity to tumor cells, we investigated the metastatic potential of MCF-7 SMAR1−/− cells. Tail-vein injections in syngeneic nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice indicated that MCF-7 SMAR1−/− cells showed a profound increase in invasive and metastatic potential, especially to the lungs, as evidenced by histopathological analysis (Fig. 2J) . Immunostaining of the histological sections of metastatic lung nodules with α-SMAR1 and -CD44 variable exon-specific antibodies indicated enhanced expression of CD44v in the metastatic nodules, wherein the amount of SMAR1 is minimal (Fig. 2K ). All together, these results indicate that knockdown or absence of SMAR1 enhances CD44 alternate exon inclusion, and the metastatic propensity served as a hallmark of CD44v inclusion.
Activation of ERK-MAPK Pathway Translocates SMAR1 to the Cytoplasm.
ERK-MAPK signaling is considered indispensable and a prerequisite for CD44 gene AS (18, 23) . Considering the similar effects exerted on CD44 gene AS upon low levels of SMAR1 and ERK-MAPK signal activation, we predicted an intricate interplay between SMAR1 expression and ERK-MAPK pathway. Towards this prediction, activation of ERK-MAPK pathway using phorbol 12-myristate 13-acetate (PMA) in HeLa cells showed no change in SMAR1 levels (SI Appendix, Fig. S2 ). However, IF analysis revealed that SMAR1, a primarily nuclear protein, translocated to the cytoplasm upon ERK activation (Fig. 3A) . This observation was reaffirmed by Western blot analysis of SMAR1 in PMA-stimulated nuclear-cytoplasmic fractions (Fig. 3B ). To further determine that SMAR1 localization is ERK-dependent, we used ERK-1/2 inhibitor U0126 and observed an abrogation in the translocation of SMAR1 to the cytoplasm ( Fig. 3 A and C) . Furthermore, treatment with a nuclear export inhibitor, Leptomycin B, also inhibited the cytoplasmic translocation of SMAR1 ( Fig. 3 A and D) , reinforcing that activated ERK-1/2 kinase induces nuclear export of SMAR1. Collectively, these results indicate that ERK-MAPK signal mimics SMAR1 knockdown by facilitating its cytoplasmic localization, thus promoting CD44 gene AS.
SMAR1 Is Accumulated Along the CD44 Gene Body and Binds to CD44
Pre-mRNA. An intricate association of chromatin remodelers with splicing machinery and the chaperoning of pre-mRNA by chromatin during AS incited us to analyze the distribution of SMAR1 along the CD44 gene locus (Fig. 3E) . Chromatin immunoprecipitation (ChIP) assays indicated an endogenous distribution of SMAR1 along the intronic and exonic regions of CD44; however, activation of the ERK-MAPK pathway reduced the same (Fig. 3F) . Furthermore, occupancy of RNA polymerase (Pol) II (19) inversely correlates with that of SMAR1 and also served as positive control (SI Appendix, Fig. S3 A and B) . Considering that some of the chromatin proteins, such as heterochromatin protein 1γ (HP1γ) and RNA Pol II, bridge the nascent pre-mRNA to the chromatin (21), we further investigated the association of SMAR1 with CD44 pre-mRNA. RIP assays revealed an intricate association of SMAR1 with CD44 pre-mRNA in untreated cells (Fig. 3G) ; however, the association was reduced upon ERK-1/2 activation (Fig. 3G , red line). The association of SMAR1 with pre-mRNA containing variable exons v3 and v5 was significantly high, indicating that SMAR1 associates with CD44 transcript and likely sequesters the variable exons from being incorporated into the mRNA.
Activated ERK-1/2 Kinase Phosphorylates SMAR1 at Threonines 345 and 360. ERK-MAPKs are classical protein kinases that phosphorylate numerous substrates with proline-directed serine/threonine residues (18, 30) . SMAR1 in its protein-association domain harbors two putative threonine followed by proline (TP) residues positioned at 345 and 360 (Fig. 4A) . Phospho-TP (pTP) assays using α-pTP antibody revealed time-dependent phosphorylation of SMAR1 upon ERK-1/2 activation (Fig. 4B) . SMAR1 phosphorylation at TP residues was observed within 15 min of ERK activation, and the levels in the nucleus decreased by 60 min (Fig. 4B , lanes 2 and 5), indicating nuclear export of phosphorylated protein. A concomitant increase of pTP-SMAR1 in the cytoplasmic fractions was observed within 15 min until 120 min of ERK activation. However, treatment with U0126 inhibited the phosphorylation of SMAR1 as well as its cytoplasmic localization (SI Appendix, Fig.  S4A ). Furthermore, in vitro kinase assay, by incubating recombinant GST-SMAR1 with activated recombinant ERK2 in a concentration-dependent manner, indicated phosphorylation of SMAR1 (Fig.  4C) . However, treatment with calf intestinal phosphatase (CIP) abated SMAR1 phosphorylation, affirming SMAR1 as a substrate of activated ERK kinase (Fig. 4D) . To further ascertain these observations, we generated threonine-to-alanine mutants (T345A/ T360A) in p3X-Flag-SMAR1. IF (Fig. 4E ) and pTP assays (Fig. 4F) , along with subcellular fractionation studies (SI Appendix, Fig. S4B ), illustrated that T345A/T360A mutants are phosphorylation-deficient and failed to exhibit cytoplasmic localization, rendering insensitivity to ERK activation. To further strengthen these observations, we generated in-house antibodies against T345/T360 phospho-SMAR1 (Pep3) and T345A/T360A mutant-SMAR1 (Pep6) (SI Appendix, Fig. S4C ). Analysis of PMA-stimulated nuclear and cytoplasmic fractions using these antibodies reaffirmed phosphorylationmediated differential localization of SMAR1 (SI Appendix, Fig.  S4D ). Despite Pep6-antibody-detected endogenous unphosphorylated SMAR1, which is primarily localized in the nucleus, it failed to recognize the cytoplasmic as well as nuclear threonine-phosphorylated SMAR1. These results confirm the specificity of the antibody as well as phosphorylation of SMAR1 at T345 and T360. To further demonstrate the biological significance of T345/ T360 phosphorylation of SMAR1 and CD44 AS, we examined the CD44 variant exon incorporation upon expression of wildtype Flag-SMAR1 (FSM) and T345A/T360A mutant Flag-SMAR1 (FSM-Mut). As depicted in Fig. 4G , unactivated cells expressing FSM, as well as FSM-Mut, showed decreased CD44v inclusion. Interestingly, activation of the ERK pathway enhanced variant exon inclusion in cells expressing either vector alone or FSM, but not in cells expressing FSM-Mut. This result can be attributed to the presence of FSM-Mut in the nucleus (Fig. 4H) , which impedes the ability of ERK-1/2 to induce a switch in CD44 variable exon inclusion. Together, these results indicate that phosphorylation of SMAR1 at T345/T360 is critical and necessary for ERK-MAPK signal-induced inclusion of CD44 variant exons.
SMAR1 Knockdown Promotes AS Independent of the ERK-MAPK
Pathway. Given that SMAR1 knockdown facilitates CD44 gene AS in a manner similar to that of activation of the ERK-MAPK pathway (23), we investigated a possible leaky activation of ERK-1/2 upon SMAR1 knockdown. Toward this hypothesis, we checked for the expression of phosphorylated ERK-1/2 (activation of ERK) in the nuclear extracts from SMAR1 knockdown HeLa cells. Interestingly, unlike the PMA-stimulated nuclear extracts that showed the presence of phospho-ERK-1/2 (Fig. 5A, lane 2) , SMAR1-knocked-down nuclear extracts did not show any of its expression (Fig. 5A, lane 4) , indicating ineffective activation of ERK-1/2. However, we observed a consistent increase in CD44 variant exon inclusion upon SMAR1 depletion (Fig. 5B, lane 4) , indicating that SMAR1 knockdown-mediated regulation of the CD44 gene AS is ERK-MAPK signal-independent. This finding incited us to investigate the molecular mechanism underlying SMAR1-mediated signalindependent regulation of AS.
SMAR1 Interacts with Sam68 in a Signal-Dependent Manner. Sam68, a STAR-family protein, associates with splice-regulatory elements on pre-mRNAs and plays a strategic role in CD44 gene AS (18) . Of significance, SMAR1 association with CD44 pre-mRNA prompted us to investigate its association with Sam68. Immunoprecipitation (IP) assays in HeLa cell nuclear extracts revealed an endogenous association of SMAR1 with Sam68 (SI Appendix, Fig. S5A) . However, the association of SMAR1 with Sam68 is prevented in ERK-activated nuclear extracts due to the differential localization of SMAR1 to the cytoplasm (Fig. 5C, lanes 2  and 6) . Furthermore, IP analysis of nuclear extracts treated with RNase A abolished the SMAR1-Sam68 interaction. (SI Appendix, Fig. S5B ). Together, these data suggest that endogenously, SMAR1 associates with Sam68 in an RNA-dependent manner, and this association is perturbed due to differential localization of SMAR1 upon activation of ERK-1/2. This finding led us to hypothesize that SMAR1 in complex with Sam68 might form an inhibitory complex that perturbs AS, which inspired us to delineate the SMAR1-Sam68 nexus that regulates AS.
Depletion of SMAR1 and/or Activation of ERK-1/2 Enhances Sam68
Acetylation. In silico docking studies of SMAR1 and Sam68 revealed that C-terminal domain (CTD) of SMAR1 (residues 248-371) associates with Sam68 and shares a complimentary shape with the lysine-rich (21 lysine residues) KH domain of Sam68 ( Fig. 5D and SI Appendix, Fig. S5 C-E and Table S2 ). PTMs on trans-factors play a decisive role during AS (18, 31, 32) , and SMAR1 modulates PTMs such as deacetylation/acetylation through its association with HDAC1. The association of SMAR1 with the lysine-rich KH domain of Sam68 led us to hypothesize that SMAR1 might modulate the acetylation/deacetylation dynamics of Sam68. IP assays using α-acetyl-lysine (α-Ac.K) antibody revealed enhanced acetylation of Sam68 upon SMAR1 knockdown (Fig. 5E, lanes 2 and 3) , despite total Sam68 levels remaining unaltered, emphasizing that endogenously Sam68 is maintained in a deacetylated state and knockdown of SMAR1 facilitates Sam68 acetylation. Because ERK activation prevents SMAR1-Sam68 association, we investigated Sam68 acetylation upon ERK activation. Consistently, we observed an accumulation of acetylated Sam68 upon ERK activation (Fig. 5F, lanes  3-6) . Of significance, acetylation kinetics of Sam68 indicated that phosphorylation of SMAR1 (Fig. 4B, 15 min) precedes Sam68 acetylation upon ERK activation (Fig. 5F, 30 min) . Strikingly, inhibition of ERK-1/2 with U0126 prevented Sam68 acetylation (SI Appendix, Fig. S5F ). Furthermore, Sam68 acetylation in SMAR1 knockdown cells treated with U0126 convincingly demonstrated that Sam68 acetylation depends on the presence or absence of SMAR1 in the nucleus (SI Appendix, Fig. S5G ). Together, these data reveal that knockdown of SMAR1 and/or activation of ERK-1/ 2 are equally effective in facilitating Sam68 acetylation.
To further establish the significance of Sam68 acetylation during AS, we generated various deletion constructs of Sam68 (Fig. 5G) and verified their acetylation status as well as the efficiency to modulate AS. Results showed that myc-Sam68 full-length (1-443), myc-Sam68 (90-443), and myc-Sam68 (90-257) are acetylated upon ERK activation (Fig. 5H, lanes 2, 4, and 8) , whereas mycSam68 (257-443), lacking lysine-rich KH domain, failed to show any acetylation (Fig. 5H, lane 6) . Acetylation of the minimal domain, myc-Sam68 (90-257), harboring 21 lysine residues, but not myc-Sam68 (257-443), emphasized that lysine residues are the target sites of Sam68 acetylation. CD44 splice reporter minigene splicing assays in MCF-7
Sam68−/− cells (SI Appendix, Fig. S5H ) indicated that the lysine-rich KH domain is indispensable for CD44 AS (SI Appendix, Fig. S5I ). In addition, we investigated whether the mechanism of Sam68 acetylation-mediated regulation is applicable during AS of other target genes. Toward this investigation, we assayed FAS minigene AS (SI Appendix, Fig. S5J ) and one of the target genes of Sam68, Bcl-X gene AS (33) (SI Appendix, Fig. S5K ). Our results from these studies indicated that acetylation of Sam68 through the mechanism of ERK activation facilitates AS. Together, these results distinctly highlight that deacetylation/acetylation switch on Sam68 is a critical regulatory event during AS.
HDAC6 in Complex with SMAR1 Deacetylates Sam68 and Regulates
AS. Next, we investigated the specific deacetylase of Sam68 that coordinates with SMAR1 and regulates AS. Our results revealed that, despite SMAR1 association with both HDAC1 (21) and Sam68, Sam68 failed to interact with HDAC1 (SI Appendix, Fig.  S6 A-C) . However, a study by Wang et al. on genome-wide occupancy of HDACs revealed the enrichment of HDAC2 and HDAC6 on to the coding regions of multiple genes (34) . An association of SMAR1 with HDAC6 (35), but not with HDAC2 (SI Appendix, Fig. S6 D and E) , and an association of HDAC6 with RNA Pol II (33) and with U5 snRNA (SI Appendix, Fig. S6F ) indicated that SMAR1 might cooperate with HDAC6 to deacetylate Sam68. Consistent with our hypothesis, IP assays clearly showed that SMAR1, as well as Sam68, associate with HDAC6 (Fig. 6A) . Concurrently, sequential IP experiments revealed the coexistence of SMAR1-HDAC6-Sam68 as a trimeric complex (Fig. 6B) . Furthermore, the existence of this trimeric complex was confirmed by size-exclusion chromatography using HeLa cell nuclear extracts (SI Appendix, Fig. S6G , Upper, fractions [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . However, the trimeric complex was observed to be RNA-sensitive because RNase A-treated nuclear extracts showed the dissociation of high-molecularweight HDAC6-SMAR1 and Sam68 complexes (SI Appendix, Fig.  S6G , Lower, fractions [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Thus, an in silico analysis of HDAC6-SMAR1-Sam68 complex in the presence of RNA component is compatible with the positioning of RNA at the interacting site of SMAR1-Sam68, and both the electrostatic and solvation energies contribute largely for the stabilization of protein-trimeric and RNA-protein-trimeric complexes (Fig. 6C and SI Appendix, Table  S3 ). Furthermore, positioning of the RNA enhances the total energy stabilization of the protein-trimeric complex (SI Appendix, Table  S4 ). Based on the above observations, it can be inferred that SMAR1, through HDAC6, maintains Sam68 in a deacetylated state.
To prove that HDAC6 plays a decisive role in the modulation of Sam68 acetylation and in turn CD44 gene AS, we investigated the consequences upon HDAC6 knockdown. Semiquantitative RT-PCR analysis of CD44 splice variants in HeLa cells that were stably knocked down with HDAC6-shRNA lentivirus revealed an increase in the incorporation of CD44 splice variants v3, v5, v6, and v7 (Fig. 6D) . Convincingly, we observed enhanced acetylation of Sam68 upon HDAC6 knockdown, indicating that HDAC6 maintains Sam68 in a deacetylated state (Fig. 6E) . Results of Sam68 acetylation (SI Appendix, Fig. S6H ) and CD44 gene AS (SI Appendix, Fig. S6I ) upon knockdown of HDAC1 showed no change in Sam68 acetylation or AS, indicating that HDAC6 is the specific deacetylase that coordinates with SMAR1 for Sam68 deacetylation. Nevertheless, to further extrapolate and establish the biological significance of SMAR1 in regulating HDAC6-mediated deacetylation of Sam68 (and subsequent AS of the CD44), we investigated Sam68 acetylation in MDA-MB-468, T47D, and MCF-7 breast cancer cells. Of significance, we observed acetylation of Sam68 in LOH-harboring MDA-MB-468 and T47D cells (Fig. 6F,  lanes 2 and 3) , which in the earlier results were shown to exhibit enhanced incorporation of CD44 variable exons (Figs. 2F and 2G ). Sam68 remained deacetylated in MCF-7 cells that do not harbor LOH. Strikingly, MDA-MB-468 and T47D cells expressed higher HDAC6 levels than MCF-7 cells (Fig. 6F) . This finding highlights the role of SMAR1 in the maintenance of Sam68 in a deacetylated state. IP assays in MCF-7 cells, which express SMAR1, maintain HDAC6-SMAR1-Sam68 complex; however, the interaction was found to be perturbed in MDA-MB-468 and T47D (Fig. 6G, Left) . Notably, the interaction of HDAC6 with Sam68 was restored upon SMAR1 expression in LOH-harboring MDA-MB-468 and T47D cells (Fig. 6G , Middle and Bottom Right). Contrastingly, MCF-7 cells that were knocked down for SMAR1 failed to show the interaction between HDAC6 and Sam68 (Fig. 6G, Upper Right) . Together, these data convincingly establish that SMAR1 is a critical mediator of the HDAC6-Sam68 interaction and that SMAR1 coordinates HDAC6-mediated deacetylation of Sam68.
Inactivation of HDAC6 Facilitates Sam68 Acetylation and AS. To further ascertain our observations of HDAC6-mediated deacetylation of Sam68 and CD44 gene AS, we used an HDAC6-specific inhibitor, tubacin. We observed that treatment of HeLa cells with tubacin resulted in the enhanced incorporation of CD44 alternate exons v3-v7 (Fig. 6H) . Furthermore, analysis of nuclear extracts from tubacin-treated HeLa cells revealed distinct acetylation of Sam68 (Fig. 6I) . Considering that HDAC6 in complex with SMAR1 deacetylates Sam68 and to establish that LOH-mediated Sam68 acetylation is key to enhance CD44 variant exon inclusion (Figs. 6F and 2G), we treated MCF-7 cells with tubacin and examined Sam68 acetylation, as well as the CD44 variant exon inclusion. Consistent with our assumption, we observed a favorable switch in the incorporation of CD44 alternate exons v3-v7 (Fig. 6J) , as well as Sam68 acetylation (Fig. 6K) . However, the variables v5 and v6 showed a decrease in incorporation after 6 h of tubacin treatment. This result can be attributed to either the toxicity or altered stability of tubacin in these cells. Together, these results ascertain that HDAC6 deacetylates Sam68, and inactivation of HDAC6 favors Sam68 acetylation, which in turn facilitates AS of the CD44 mRNA.
Discussion
Our present study delineates a complex regulatory network underlying the signal-dependent and -independent regulation of cotranscriptional AS by SMAR1 (Fig. 7) . Endogenously, SMAR1 in complex with HDAC6 associates with Sam68 and maintains it in a deacetylated state, consecutively inhibiting CD44 variant exon inclusion. Alternatively, activation of the ERK-MAPK pathway, which is considered to be indispensable for CD44 gene AS, disrupts the HDAC6-SMAR1-Sam68 complex, enhancing Sam68 acetylation, which results in cotranscriptional inclusion of CD44 gene variant exons. Similarly, knockdown of SMAR1, which also favors Sam68 acetylation independent of ERK-MAPK pathway signaling, enhances CD44 gene AS. Together, these results emphasize the significance of Sam68 acetylation in the context of regulated splicing.
SMAR1 is a scaffold/matrix attachment region-binding protein that regulates gene expression by binding to various promoter elements (11, 12) . Here, we show that SMAR1 is enriched in the nuclear speckles, which are the sites for the association of actively transcribing genes, wherein chromatin modulators, splicing factors, snRNPs, and hnRNPs are aggregated (24) . Association of SMAR1 with the spliceosome components U1, U2, U4, U5, and U6 snRNAs provided our initial insights into the role of SMAR1 in splice site selection. It is noted that certain other NM factors, such as SAFB1 and SAFB2, are also reported to modulate the alternative exon inclusion (36, 37) .
Cancer cells often express aberrant splice variants due to altered expression of trans-factors. For instance, enhanced expression of the hnRNP A1/A2 and PTB represses the inclusion of exon 9 in the pyruvate kinase M gene, which contributes to the Warburg effect in cancer cells (16) . Similarly, CD44 gene AS distinctly illustrates the role of variable exons during the metastasis of various tumors (22, 28) . Our findings underscore the significance of SMAR1-mediated CD44 gene splicing in the context of breast cancer metastasis. The ERK-MAPK pathway substantially enhances the inclusion of CD44 variant exons (23) . Proteins such as Sam68, SRm160, Brm, and HP1γ that regulate CD44 pre-mRNA splicing are substrates of ERK kinase (18, 20, 21) . Given that SMAR1 knockdown enhances CD44 variant exon inclusion, we observed phosphorylation-mediated translocation of SMAR1 from nucleus to the cytoplasm upon ERK activation, thus mimicking SMAR1 knockdown. As such, our data provide further insights into the mechanism through which the ERK-MAPK pathway induces CD44 variant exon inclusion. Mutation of FSM at T345A/T360A, which is phosphorylation-deficient, failed to translocate to the cytoplasm upon ERK activation, inhibiting CD44 alternate exon inclusion. ChIP and RIP assays that indicated association of SMAR1 with the chromatin and CD44 pre-mRNA highlighted an inverse correlation in the occupancy of Brm, HP1γ, and RNA Pol II upon ERK activation (19, 21) . Because SMAR1 knockdown favors CD44 alternate exon inclusion, the possibility of increased occupancy of Brm and HP1γ under such a scenario, which in turn enhances the occupancy of serine 5 phospho-RNA Pol II, cannot be ruled out. This possibility might be one of the contributing factors that enhance CD44 gene AS upon SMAR1 knockdown, because RNA Pol II with decreased elongation rate facilitates the use of weaker splice sites (38) .
Despite failed activation of ERK-1/2 upon SMAR1 knockdown, increased inclusion of CD44 alternate exons indicates the existence of a noncanonical pathway for CD44 gene AS. Because PTMs are known to play a key regulatory role during a majority of the cellular events, we investigated possible PTMs that Sam68 could acquire through SMAR1. ERK-1/2 is known to induce phosphorylation of Sam68 (18) ; however, failed activation of ERK-1/2 upon SMAR1 knockdown highlighted the dispensability of Sam68 phosphorylation. The association of SMAR1 with HDAC1 was earlier reported to regulate p53 transactivation potential via deacetylation/acetylation (12) , which is in agreement with the concept that PTMs such as acetylation provide a regulatory layer during many cellular events (39) . Our present work shows that endogenous Sam68 is maintained in a deacetylated state and knockdown of SMAR1 enhances Sam68 acetylation. A stable association of SMAR1 with the lysine-enriched KH domain of Sam68 strongly supports the concept that these lysines are masked from being acetylated during the interaction. ERK-MAPK signal-induced disruption of SMAR1-Sam68 association facilitates Sam68 acetylation that was abated in the presence of ERK inhibitor U0126. It is noted that extracellular stimuli, which induce protein phosphorylation, mark a first wave of PTMs that can be further converted to acetylation-based events (38) . Thus, our study is in agreement with this hypothesis and depicts that ERK-1/2-mediated phosphorylation of SMAR1 and Sam68 (18) is a prerequisite to disrupt their association, resulting in Sam68 acetylation during signal-dependent alternate exon inclusion. A study using various deletion and mutant constructs of Sam68 distinctly highlighted the role of Sam68 KH-domain lysine residues and the requirement for Sam68 acetylation during AS of CD44. Because the pattern of acetylation alters the mechanistic impact, acetylation at a cluster of lysine residues results in the formation of charged patches (39) , which in turn might enhance the affinity of Sam68 toward RNA. Together, Sam68 acetylation favors the inclusions of exons with weak splice sites and thus might be offering a fail-safe mechanism of CD44 gene AS during embryogenesis.
Deacetylation of Sam68 by SMAR1 in cooperation with HDAC6 highlights the fact that the SMAR1-HDAC1 pool, which is mostly localized at gene promoters, is distinct from SMAR1-HDAC6-Sam68 pool that localizes to the CD44 gene body and regulates AS. The basis for the specificity of HDAC6 association with Sam68 can be attributed to its differential occupancy. HDAC1 and HDAC3 are mostly localized to promoters, whereas HDAC2 and HDAC6 are enriched on the gene body as well as promoters (35) . The association of HDAC6 with RNA Pol II (35) further contributes to the HDAC6-mediated deacetylation of Sam68. In this case, it is tempting to speculate that HDAC6 could also modulate the elongation rate of RNA Pol II via deacetylation of additional transcriptional elongation and splicing factors that are bound to the CTD tail, resulting in regulated splicing through an alternative mechanism.
This previously unidentified molecular mechanism of regulated AS via Sam68 acetylation adds an extra dimension in understanding cancer prognosis, especially in breast cancer. Our data, to our knowledge, for the first time show that LOH at 16q24.3 locus in breast cancer cells is associated with low levels of SMAR1 and enhanced Sam68 acetylation, which in turn favors CD44 variant exon inclusion and metastasis. MCF-7 cells, without LOH, express SMAR1 and maintain Sam68 in a deacetylated state, resulting in significantly low levels of CD44 variable exons. Despite the presence of relatively high levels of HDAC6 in MDA-MB-468 and T47D compared with MCF-7, our work suggests that Sam68 is maintained in an acetylated state in these cells due to their lack of SMAR1, which is indispensable for the colocalization of HDAC6 and Sam68. Despite decreased incorporation of proximal variant exons upon restoration of SMAR1 expression in LOH-harboring cells, the distal exons remain unaltered. This observation highlights that there are some other contributing factors encoded from the 16q24 locus, which might modulate the incorporation of CD44 distal variant exons. Alternatively, enhanced interaction of Sam68 with the U5 snRNA upon ERK activation (19) and endogenous association of SMAR1 with U5 snRNA indicates that in addition to modulation of Sam68 acetylation, cooperation between SMAR1 and HDAC6 might act as "roadblock" to sequester U5 snRNA from Sam68, thus preventing the splice site selection.
In summary, our study elucidated a previously unappreciated regulatory mechanism used to control alternate exon use, whereby the NM-associated protein SMAR1 and chromatin-modifying enzyme HDAC6 modulate the acetylation of splicing factors like Sam68 to modulate AS in response to extracellular cues (Fig. 7) . To our knowledge, we show for the first time that HDAC6 plays a pivotal role in regulated splicing of CD44 via Sam68 deacetylation. Our findings reveal that knockdown or reduced levels of SMAR1 promotes cancer cell invasion and metastasis, whereas overexpression restricts cell invasion. This finding suggests that targeting Sam68 acetylation may provide alternative therapeutic strategies during breast cancer metastasis. Thus, we provide a previously unidentified mechanism of regulation of AS in the etiology of human breast cancer.
Materials and Methods
Additional materials and methods on plasmids, antibodies, chromatin immunoprecipitation, and RNA immunoprecipitation, as well as on the modeling and docking studies, are provided in SI Appendix, SI Materials and Methods.
Cells and Cell Culture. HEK 293T, HeLa, and MCF-7 cells were cultured in DMEM supplemented with 10% (vol/vol) FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin (Invitrogen) at 37°C and 5% CO 2 . MDA-MB-468 and T47D cells were grown in L-15 and RPMI medium under similar conditions. Adenovirus and Lentivirus. SMAR1 adenovirus was used as described (12) . For SMAR1, HDAC6, and Sam68 lentivirus generation, HEK 293T cells were cotransfected with pSPAX, pMD2.G, SMAR1-shRNA (Clone ID: V2LHS_174233; V3LHS_374011; V3LHS_374008; RHS4346 for nonsilencing; Open Biosystems), HDAC6-shRNA [Clone ID: TRCN0000004839 (sh1); TRCN0000004840 (sh2)], or Sam68-shRNA (Clone ID: TRCN0000000044-TRCN0000000047; TRCN0000000104). Indicated cell lines were transduced with a 1:1 mix of viral supernatant and growth medium. Stable cell lines were selected with 1.5 μg/mL puromycin (Sigma).
